Nipocalimab

Unassigned

New Medicines

Autoimmune haemolytic anaemia, warm type

Information

New molecular entity
Janssen
Momenta

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

FcRn inhibitor to reduce circulating IgG antibodies
Incidence of autoimmune haemolytic anaemia is 1 in 80,000 to 100,000 population/year in Caucasians. It is slightly more common in females than in males and typically presents in middle-aged and older individuals [2].
Autoimmune haemolytic anaemia, warm type
Bladder instillation